BioGaia have performed several years of research on new and unique probiotic strains for specific indications and have now been granted a patent in the USA related to anti-inflammatory use of certain strains of probiotic lactobacilli.
Anti-inflammatory lactobacilli can stop inflammation, which opens up a wide area of use.
A specific area where the use of anti-inflammatory lactobacilli is of interest is inflammation associated with Helicobacter pylori infection. Helicobacter pylori in the stomach can lead to gastritis and ulcers and can even lead to stomach cancer. Anti-inflammatory lactobacilli can counteract such damaging inflammation.
Earlier, BioGaia´s researchers have shown that Reuteri survives and colonises the human stomach and there directly reduces the number of Helicobacter pylori, which reduces the level of infection.
"The new patent is an important step in the work of developing a new generation of probiotics which are directed at specific indications. Inflammation by Helicobacter pylori is such an indication which affects a large proportion of the population." says Peter Rothschild MD, BioGaia AB.